aTyr’s Immunomodulatory Therapy ATYR1923 Wins Orphan Drug Status

aTyr’s Immunomodulatory Therapy ATYR1923 Wins Orphan Drug Status

316303

aTyr’s Immunomodulatory Therapy ATYR1923 Wins Orphan Drug Status

The U.S. Food and Drug Administration has granted orphan drug designation to aTyr Pharma’s experimental immunomodulatory molecule ATYR1923 for the treatment of sarcoidosis. The therapy is being developed for severe inflammatory diseases affecting the lungs, which in sarcoidosis patients is called pulmonary sarcoidosis. Orphan drug status is given to treatment candidates with the potential to be safe and effective in rare diseases — defined in the U.S. as those affecting fewer than 200,000 people — with no…

You must be logged in to read/download the full post.